During 3 years treatment of primary progressive multiple sclerosis with glatiramer acetate, specific antibodies switch from IgG1 to IgG4.
In this study we analyzed the humoral immune response to glatiramer acetate in 16 GA-treated primary progressive MS patients and 9 placebo patients from the PROMiSe study. We have demonstrated that all multiple sclerosis patients (n=16) continuously treated with GA for 3 years developed anti-GA antibodies that peaked at month 3 and remained elevated during the whole study. We have also demonstrated that initially GA-reactive antibodies of the IgG1 subclass predominate, peaking at month 9 of therapy, but after 9 months IgG1 decreases while anti-GA antibodies of the IgG4 subclass increase and remain high for the 3 years of follow-up. These results support a shift from Th1 to Th2 in the antibody response to glatiramer acetate treatment.
Basile
Erika
E
University of British Columbia, Department of Medicine, Room S-159, 2211 Wesbrook Mall, Vancouver, BC, Canada V6T 2B5.
Gibbs
Ebrima
E
Aziz
Tariq
T
Oger
Joel
J
D000918:Antibody Specificity; D002478:Cells, Cultured; D004311:Double-Blind Method; D005260:Female; D000068717:Glatiramer Acetate; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood*; D007166:Immunosuppressive Agents / Q000276:immunology / Q000627:therapeutic use; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000276:immunology; D008137:Longitudinal Studies; D008297:Male; D020528:Multiple Sclerosis, Chronic Progressive / Q000097:blood / Q000188:drug therapy* / Q000276:immunology*; D010455:Peptides / Q000276:immunology* / Q000627:therapeutic use*; D018417:Th1 Cells / Q000187:drug effects / Q000276:immunology; D018418:Th2 Cells / Q000187:drug effects / Q000276:immunology; D013997:Time Factors; D015854:Up-Regulation / Q000187:drug effects / Q000276:immunology
D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D010455:Peptides; D000068717:Glatiramer Acetate